Not yet recruitingPhase 3NCT06903884

3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis

Studying Vernal keratoconjunctivitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: The University of Hong Kong
Principal Investigator: Kendrick Co Shih
The University of Hong Kong, Grantham Hospital
Intervention: 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion(drug)
Enrollment: 94 target
Eligibility: 6 years · All sexes
Timeline: 2025 – 2028

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06903884 on ClinicalTrials.gov

Other trials for Vernal keratoconjunctivitis

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06913790
Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids
Superior University

See all trials for Vernal keratoconjunctivitis →

← Back to all trials